Additionally, PXR decreases gluconeogenesis by antagonizing the ability of PGC-1α to interact with HNF-4α [264] and also by repressing FOXO1, which has been demonstrated to contribute to increased gluconeogenesis in NAFLD [265]. Here, NR1I2 is linked to metabolic dysfunction-associated steatotic liver disease.